Changes in neurotransmitters in multiple sclerosis

被引：47

作者：

Barkhatova V.P. ^{[1
]}

Zavalishin I.A. ^{[1
]}

Askarova L.Sh. ^{[1
]}

Shavratskii V.Kh. ^{[1
]}

Demina E.G. ^{[1
]}

机构：

[1] Institute of Neurology, Russian Academy of Medical Sciences, Moscow

来源：

Neuroscience and Behavioral Physiology | 1998年 / 28卷 / 4期

关键词：

Multiple Sclerosis; Multiple Sclerosis Patient; Terbutaline; Excitatory Amino Acid; Acute Disseminate Encephalomyelitis;

D O I：

10.1007/BF02464784

中图分类号：

学科分类号：

摘要：

Patients with multiple sclerosis were found to have increased cerebrospinal fluid, noradrenaline, and excitatory amino acid (glutamate and aspartate) levels, with increased blood glutamine, asparagine, and glycine levels. An association was found between these biochemical parameters and the nature and severity of neurological symptoms, as well as with the course of the disease. Neurotransmitters are proposed to have a role in the pathogenesis of multiple sclerosis, particularly in the biochemical mechanisms of the relationship between the nervous and immune systems, as well as in the neurochemical mechanisms underlying the development of neurological deficit. ©1998 Plenum Publishing Corporation.

引用

页码：341 / 344

页数：3

共 15 条

[1]

Larskii E.G., Barkhatova V.P., Demin E.G., Lab. Delo, 9, pp. 519-522, (1985)

[2]

Bellinger D.L., Lorton D., Felten S.Y., Int. J. Immunopharmacol., 14, 3, pp. 329-344, (1992)

[3]

Chelmicka-Schorr E., Arnason B.G., Ann. Neurol., 36, SUPPL., pp. 29-32, (1994)

[4]

Compston A., Ann. Neurol., 36, SUPPL., pp. 146-150, (1994)

[5]

Davidoff R.A., The Origin and Treatment of Spasticity, pp. 63-91, (1990)

[6]

Dijkstra C.D., Van Der Voort E.R., De Groot C.J., Et al., Psychoneuroendocrinology, 19, 2, pp. 135-142, (1994)

[7]

Gallai V., Sarchielli P., Firenze C., Et al., Acta Neurologica Belgica, 94, 1, pp. 44-52, (1994)

[8]

Jackson J., Cross R., Walker R., Immunology, 54, pp. 505-512, (1985)

[9]

Karaszewski J.W., Reder A.T., Anlar D., Et al., Ann. Neurol., 30, pp. 42-47, (1991)

[10]

Karaszewski J.W., Reder A.T., Anlar D., Arnason G.W., J. Neuroimmunol., 43, 1-2, pp. 1-7, (1993)

← 1 2 →